Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

S-23 60 caps

S-23 60 caps

S-23 10 mg × 60 capsules is a non-steroidal SARM from the arylpropionamide class, a full androgen receptor agonist with one of the highest affinities and limited tissue selectivity. Research Use Only reagent for research on androgen receptor pharmacology and tissue selectivity of SARMs.

47,99 €
With code BLACK: 38,39 € Lowest price in the 30 days before the discount: 47,99 €
Fast shipping
Free delivery from 350 €
Returns policy

S-23 10 mg 60 capsules - non-steroidal SARM, full androgen receptor agonist

  • S-23: a non-steroidal selective androgen receptor modulator.
  • 10 mg per capsule; pack of 60 capsules.
  • Research Use Only reagent, not a medicinal product.

Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.

S-23 is a non-steroidal selective androgen receptor modulator (SARM) from the arylpropionamide class, developed in the first decade of the 21st century by a team GTx Inc. (James T. Dalton, Amanda Jones and associates) as a candidate for hormonal male contraception. The team’s landmark study – Jones et al. 2009 (Endocrinology) – described in a rat model the ability of S-23 to reversibly inhibit spermatogenesis while maintaining the anabolic effect in muscle and bone, which distinguished this compound from previous arylpropionamide ligands tested by the same center (Andarine/S-4, bicalutamide).

In a chemical context, S-23 belongs to the family arylpropionamides — structural derivatives of the non-steroidal anti-androgen bicalutamide, from which Andarine (S-4) is also derived. Modifications of the halogen substituents in the S-23 molecule shift its pharmacological profile from partial agonism/antagonism (typical of earlier arylpropionamides) towards full, strong androgen receptor (AR) agonism with one of the highest affinities reported for this class (Ki in the order of single nanomoles).

This reagent is supplied in a 60 capsules of 10 mg S-23 — form adapted to chronic oral exposure protocols in in vivo models on rodents and to standardize the dose in long-term androgen studies. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.

Regulatory status 

S-23 has not completed any phase of human clinical trials – the entire evidence base comes from preclinical models (rat, mouse, cell cultures). No registration as a drug with the EMA, FDA or anywhere in the world. Not authorized by EFSA as an ingredient of a dietary supplement. S-23 as a SARM is on the WADA Prohibited List in category S1.2 (other anabolic agents) – a permanently prohibited substance, both in competition and out of competition. Marketing the product as an “oral muscle gainer”, “testosterone alternative” or “male contraception” is inconsistent with the Research Use Only framework.

Context of SARMs and the androgen receptor

Selective androgen receptor modulators (SARMs) is a class of nonsteroidal binding ligands androgen receptor (AR) — a nuclear transcription factor that, after binding androgen (testosterone, dihydrotestosterone), regulates the expression of genes responsible for the development and maintenance of androgen-dependent tissues: skeletal muscles, bones, prostate, gonads, hair follicles. The assumption of the SARM program, conducted since the 1990s, includes, among others: by GTx Inc. and Ligand Pharmaceuticals, was to obtain tissue selectivity — an anabolic compound in muscle and bone, but with limited action in the prostate and skin, which would theoretically reduce the side effect profile of classic androgenic-anabolic steroids.

The mechanism of tissue selectivity of SARMs is based on differences in conformation of the ligand-receptor complex and v recruitment of transcriptional coregulators (coactivators and corepressors), whose expression profile differs between tissues. An AR-binding ligand in one conformation can recruit coactivators in the muscle (agonistic effect) and corepressors in the prostate (weaker or antagonistic effect).

This dissociation is the basis of the pharmacology of the entire class. The S-23 occupies a special and in many respects extreme position in this class:

  • Full AR agonism — unlike tissue-selective ligands such as RAD-140 or LGD-4033, S-23 behaves as a full androgen receptor agonist, with very high affinity (Ki of ~1.7 nM – one of the highest among the characterized SARMs)
  • Strong anabolic effect — in rodent models, S-23 induced an increase in the mass of the levator ani muscle and the maintenance of muscle mass more strongly than weaker arylpropionamide ligands
  • Less tissue selectivity — full agonism also covers the prostate and vesicular sex glands; S-23 is therefore less “selective” in the sense of the original SARM definition than a compound such as Ostarine
  • Contraceptive potential — strong inhibition of spermatogenesis (reversible azoospermia in a rat model) by suppression of the hypothalamic-pituitary-gonadal (HPG) axis
  • No conversion to estrogen — as a non-steroidal compound, S-23 is not an aromatase substrate

The world of androgen pharmacology is watching S-23 for three reasons. Firstly, as a model compound for research on hormonal male contraception — is the original context in which it was developed. Secondly, as a research tool limits of tissue selectivity of SARMs — S-23 represents the “full agonist” end of the spectrum, opposed to tissue-selective ligands. Thirdly, as a representative of arylpropionamides with the highest affinity for AR, useful in structure-activity relationship (SAR) studies of the entire family.

What is S-23?

Chemically, S-23 is a non-steroidal androgen receptor ligand from the arylpropionamide family.

  • Common name: S-23, S23
  • Pharmacological class: non-steroidal SARM (selective androgen receptor modulator); arylpropionamide, a structural analogue of Andarine (S-4) and bicalutamide
  • Receptor profile: full AR agonist, Ki affinity ~1.7 nM
  • CAS number: 1010396-29-8 (in case of uncertainty – “to be verified in the batch COA”)
  • Molecular formula: C₁₈H₁₃ClF₄N₂O₃
  • Molar mass: 416.75 g/mol
  • Laboratory of origin: GTx Inc. (Memphis), Dalton and Jones team, 2009–2011
  • Delivered form: HPMC hard capsule (vegan), 10 mg of active substance per capsule, 60 capsules; pharmaceutical grade ≥98% HPLC

Table of physicochemical characteristics

Parameter Value
Name S-23 (S23)
Chemical class arylpropionamide (non-steroidal SARM)
Pharmacological profile full androgen receptor (AR) agonist
AR affinity Ki ~1.7 nM (one of the highest among SARMs)
CAS 1010396-29-8
Molecular formula C₁₈H₁₃ClF₄N₂O₃
Molar mass 416.75 g/mol
Purity ≥98% HPLC
Form HPMC capsule, 10 mg/capsule, 60 capsules
Half-life (rodent model) T½ ~12 h
Oral bioavailability (rodents) ~70–80%
Conversion to estrogen none (non-steroidal compound)
Clinical status no completed phase I-III studies in humans
WADA status Prohibited List, Category S1.2 – Permanently prohibited

Origin: Arylpropionamides as a class originate from work on nonsteroidal antiandrogens (bicalutamide, hydroxyflutamide) carried out at the end of the 20th century. SARM program at GTx Inc. (Memphis), led by James T. Dalton, led to the characterization of a series of arylpropionamide ligands, including Andarine (S-4) and, in a subsequent iteration, S-23. The molecule was designed for stronger, more “full” AR agonism and for use in hormonal male contraception; the first detailed characteristics were published in 2009–2011 (Jones et al., Endocrinology; conference reports of the GTx team).

Mechanism of action at the molecular level

S-23 binds directly to the ligand-binding domain of the androgen receptor (AR), stabilizing the activating conformation for the recruitment of transcriptional coactivators. Very high affinity (Ki ~1.7 nM) and a full agonist profile distinguish this compound from tissue-selective SARMs with milder characteristics. Pharmacological profile observed in preclinical models:

  1. Full androgen receptor agonism — S-23 binds AR with one of the highest affinities reported for the SARM class (Ki ~1.7 nM) and activates the receptor as a full agonist. In reporter models of androgen-dependent transcription, the compound induces a full transcriptional response, not a partial one – which contrasts with the antagonistic-partial profile of its structural relative, Andarine (S-4).
  2. Strong anabolic effect in the muscle — in a rat model (classic Hershberger test, levator muscle mass nor), S-23 induced an increase in muscle mass more strongly than weaker arylpropionamide ligands; the anabolic profile in muscle and bone was one of the main points of characterization of the GTx syndrome. In a practical context, this group includes commercially available research reagents such as RAD-140 (Testolone) and LGD-4033 (Ligandrol)
  3. Limited tissue selectivity — contrary to the original definition of a “selective” modulator, full S-23 agonism also covers androgen-dependent tissues such as the prostate and seminal vesicles; compound is therefore closer to the profile of a full androgen than a tissue-selective ligand. This is the main distinction from RAD-140/LGD-4033
  4. Inhibition of spermatogenesis – contraceptive potential — in a rat model (Jones et al. 2009), S-23 caused reversible azoospermia by suppressing the secretion of gonadotropins LH and FSH, leading to the arrest of spermatogenesis; After discontinuing the compound, fertility returned. This is the original context for the development of the molecule – hormonal male contraception
  5. Strong suppression of the HPG axis — through S-23 feedback, it inhibits the hypothalamic-pituitary-gonadal axis (reduction of LH/FSH and, consequently, endogenous testosterone production); in the research literature on androgen protocols, HPG axis suppression is a factor for which pericycle restorative treatment (PCT) is considered in models. This is a pharmacological observation, not an instruction for use in humans
  6. No conversion to estrogen — as a non-steroidal compound, S-23 is not an aromatase substrate, so it is not converted to estradiol (unlike testosterone and some anabolic steroids)

Pharmacokinetic profile (based on preclinical models):

  • Half-life (T½) in a rodent model: ~12 h
  • Oral bioavailability in rodents: ~70–80% (compound well absorbed after oral administration)
  • Human PK profile: uncharacterized – no phase I studies
  • Molecular target: androgen receptor (AR) ligand-binding domain; full activation of androgen-dependent transcription

S-23 among SARMs – position on the tissue selectivity spectrum: In the SARM compound class, they differ in the degree of tissue selectivity and the strength of AR agonism – from mild ligands to full agonists:

Compound AR profile Tissue selectivity Status
MK-2866 (Ostarine) partial/moderate agonist high (anabolic, gentle on the prostate) RUO; WADA S1.2
LGD-4033 (Ligandrol) strong agonist moderate–high RUO; WADA S1.2
RAD-140 (Testolone) strong agonist moderate–high RUO; WADA S1.2
S-4 (Andarine) partial agonist/antagonist high RUO; WADA S1.2
S-23 full agonist (Ki ~1.7 nM) low–moderate (includes prostate) RUO; WADA S1.2

The S-23 stands out because of what it represents end of the “full agonist” spectrum — the strongest binding and the least “selective” in the sense of the original definition of SARM. This makes it a model reagent for testing the limits of the concept of tissue selectivity and for research on androgen contraception. Structurally related S-4 (Andarine) lies at the opposite end of the spectrum – as a partial agonist/antagonist it is a reference in comparative SAR analyzes of arylpropionamides. The mechanistically related myostatin pathway modulator YK-11 (5 mg) is sometimes combined with S-23 in anabolic compound RUO analyses.

Applications in scientific research

S-23 is used in research work in several areas. In vivo models (Sprague-Dawley rat, mouse) examine its effect on the mass of the levator muscle and bone mass (anabolic effect), on the level of LH/FSH gonadotropins and parameters of spermatogenesis (contraceptive potential), on the mass of the prostate and seminal vesicles (assessment of tissue selectivity) and on cardiovascular and lipid markers (safety profile). In vitro models (androgen-dependent cell lines, AR transcription reporter tests) measure receptor affinity, transcription activation kinetics and structure-activity relationship analyses. Specific research directions include:

  • Hormonal male contraception — original context of the study; studies on the reversible suppression of spermatogenesis by modulating the HPG axis and stopping the production of gonadotropins
  • Limits of tissue selectivity of SARMs — S-23 as a model full agonist opposed to tissue-selective ligands; mapping of conformation-recruitment relationships of coregulators
  • Androgen receptor affinity and pharmacology studies — Ki characterization, transcription reporter tests, full versus partial agonist profile
  • Structure-activity analyzes (SAR) of arylpropionamides — comparison of S-23 with Andarine (S-4) and bicalutamide in terms of the influence of halogen substituents on the agonist profile
  • Androgenic safety assessment models — studies on the impact of full AR agonism on the lipid profile (including HDL reduction observed in models), hepatic and cardiovascular parameters

A broader summary of the profiles of individual ligands and the criteria for their selection in research work is presented in the guide SARMs for bodybuilders, sorting out the differences between compounds of this class.

Summary

S-23 (10 mg × 60 capsules) is a non-steroidal SARM from the arylpropionamide class, developed at GTx Inc. (the Dalton and Jones team, 2009–2011) as a candidate for hormonal male contraception. Compound stands out full androgen receptor agonism with one of the highest affinities in the class (Ki ~1.7 nM) and limited tissue selectivity — which distinguishes it from tissue-selective ligands such as RAD-140 and LGD-4033.

In rodent models, S-23 induced a strong anabolic effect in muscle and bone and reversible azoospermia by suppressing the HPG axis and decreasing the gonadotropins LH/FSH (Jones et al. 2009). As a non-steroidal compound, it is not subject to aromatization. Pharmacokinetic profile in a rodent model: T½ ~12 h, oral bioavailability ~70–80%; data in humans uncharacterized.

HPLC purity ≥98%, MS Q-TOF, COA for each batch. Regulatory Status – Research Use Only; no clinical phase in humans; WADA Prohibited List, category S1.2 (permanently prohibited).

Bibliography

  1. Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT (2009). Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for male hormonal contraception. PubMed
  2. Jones A, Hwang DJ, Duke CB 3rd, He Y, Siddam A, Miller DD, Dalton JT (2010). Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. PubMed
  3. Chen J, Hwang DJ, Bohl CE, Miller DD, Dalton JT (2005). A selective androgen receptor modulator for hormonal male contraception. PubMed
  4. Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW (2019). Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. PubMed
  5. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT (2008). Selective androgen receptor modulators in preclinical and clinical development. PubMed